BreezeBio, formerly known as GenEdit, has closed $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and expand its NanoGalaxy delivery platform.
The South San Francisco-based biotechnology company said the rebrand to BreezeBio reflects its transition from a delivery-focused platform company to a therapeutics developer focused on scalable genetic medicines with curative potential.
The company’s lead therapeutic candidate, BRZ-101, is an immune modulation therapy designed to restore tolerance in type 1 diabetes. The therapy delivers autoantigens encoded by mRNA and tolerogenic co-factors to antigen-presenting cells, which then present the antigens to T cells in a tolerance-inducing context. This process is designed to generate antigen-specific regulatory T cells that block autoimmune responses without impairing overall immune function.
In preclinical studies, BRZ-101 induced antigen-specific immune tolerance in multiple autoimmune disease models, including the NOD mouse model of diabetes, and was well tolerated in mice and non-human primates. BreezeBio is advancing the candidate into IND-enabling studies.
The company’s therapeutic pipeline is powered by its proprietary NanoGalaxy platform, which enables targeted, non-viral delivery of genetic payloads, including mRNA, across immune, cardiac, pulmonary, and central nervous system tissues. Delivery specificity is driven by the physicochemical properties of the polymers used to encapsulate payloads and form nanoparticles. BreezeBio is also expanding the platform through ligand conjugation to enhance tissue and cell specificity, including delivery to T cells for potential in vivo CAR-T therapeutic development.
Alongside its internal pipeline, BreezeBio continues to advance its multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group. Following a previously achieved milestone and associated payment, research and development activities under the collaboration remain ongoing.
The Series B round was led by new investors Yuanta Investment and DSC Investment, with participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others. Existing investors including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners also joined the financing.
BreezeBio is headquartered in the South San Francisco area and is developing genetic medicines targeting autoimmune diseases and oncology indications.
KEY QUOTES
“Now that we can deliver genetic payloads to the right cells with precision, we are building genetic medicines designed to make a real difference for patients. We’ve completed our transition from a delivery platform to a therapeutics company, and this financing allows us to advance our first internal programs toward the clinic while continuing to expand the reach of NanoGalaxy.”
Kunwoo (Ryan) Lee, Ph.D., Chief Executive Officer Of BreezeBio
“BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery, and in doing so is helping define the next generation of genetic medicines. With platform validation through the company’s strategic collaboration and milestone achievement with a global biotech partner and clear progress toward clinical development, BreezeBio is approaching an important inflection point as it advances a differentiated internal pipeline designed to address significant unmet needs in autoimmune and other serious diseases. We believe BreezeBio is positioned to become a global genetic medicines developer, and Yuanta is committed to supporting that journey.”
Vincent Jeong, Managing Director At Yuanta Investment, Manager Of The Ministry Of Health, And Lead Investor In The Series B Financing
